Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.41 |
| ▸ | CALCA | P06881 | 9/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094063 | 0.91 | MEN1 (0.42) | PHGDHPDE2AMEN1KMT2AMMP9 | |
| SCHEMBL6095823 | 0.90 | PHGDH (0.47) | PHGDHCALCABACE1BACE2 | |
| SCHEMBL6095294 | 0.90 | PHGDH (0.47) | PHGDHCALCABACE1BACE2 | |
| SCHEMBL6093749 | 0.87 | PHGDH (0.43) | PHGDHCALCABACE1BACE2 | |
| SCHEMBL6096233 | 0.87 | POLB (0.42) | — | |
| SCHEMBL6094424 | 0.87 | PHGDH (0.41) | PHGDHPDE2ACALCACNR2 | |
| SCHEMBL6094115 | 0.86 | PHGDH (0.42) | PHGDHPDE2ACALCABACE1BACE2 | |
| SCHEMBL6095571 | 0.86 | CALCA (0.44) | PHGDHPDE2ACALCAMEN1KMT2A | |
| SCHEMBL6095159 | 0.86 | PHGDH (0.42) | PHGDHPDE2ACALCAKMT2ABACE1 | |
| SCHEMBL6094054 | 0.85 | CALCA (0.43) | PHGDHPDE2ACALCACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | claimed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| US-7135467-B2 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-14 | — | — | US | disclosed |
| US-20040204498-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204498-A1 | HIV integrase inhibitors | IMPDH1, TYMP, REV1 | PHGDH 1699/4885PDE2A 1238/4885CALCA 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.